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Abstract
Background: Abnormal levels of Heat Shock Proteins (HSPs) have been observed in many human
neoplasms including breast cancer and it has been demonstrated that they have both prognostic
and therapeutic implications. In this study, we evaluated immunohistochemical expression of HSPs
in normal and neoplastic canine mammary glands and confronted these results with overall survival
(OS), in order to understand the role of HSPs in carcinogenesis and to establish their potential
prognostic and/or therapeutic value.
Methods: Immunohistochemical expression of Hsp27, Hsp72, Hsp73 and Hsp90 was evaluated in
3 normal canine mammary glands and 30 malignant mammary tumours (10 in situ carcinomas, 10
invasive carcinomas limited to local structures without identifiable invasion of blood or lymphatic
vessels, 10 carcinomas with invasion of blood or lymphatic vessels and/or metastases to regional
lymph nodes). A semi-quantitative method was used for the analysis of the results.
Results: Widespread constitutive expression of Hsp73 and Hsp90 was detected in normal tissue,
Hsp72 appeared to be focally distributed and Hsp27 showed a negative to rare weak
immunostaining. In mammary tumours, a significant increase in Hsp27 (P < 0.01), Hsp72 (P < 0.05)
and Hsp90 (P < 0.01) expression was observed as well as a significant reduction in Hsp73 (P < 0.01)
immunoreactivity compared to normal mammary gland tissue. Hsp27 demonstrated a strong
positivity in infiltrating tumour cells and metaplastic squamous elements of invasive groups. High
Hsp27 expression also appeared to be significantly correlated to a shorter OS (P = 0.00087).
Intense immunolabelling of Hsp72 and Hsp73 was frequently detected in infiltrative or
inflammatory tumour areas. Hsp90 expression was high in all tumours and, like Hsp73, it also
showed an intense positivity in lymphatic emboli.
Conclusion: These results suggest that Hsp27, Hsp72 and Hsp90 are involved in canine mammary
gland carcinogenesis. In addition, Hsp27 appears to be implicated in tumour invasiveness and its
high immunodetection in invasive tumours is indicative of a poorer clinical outcome.
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Background
Heat Shock Proteins (HSPs) or Stress Proteins are one of
the most evolutionarily conserved classes of molecule and
play a fundamental role in the maintenance of cellular
homeostasis. Under physiological conditions, they act as
"molecular chaperones", by assisting protein folding,
transport and degradation; during stress, on the other
hand, they prevent aggregation and promote refolding of
damaged proteins. HSPs are classified into several fami-
lies, named according to their approximate molecular
weight [1]. The 27-kDa Heat Shock Protein (Hsp27) is an
actin-associated protein, predominantly expressed in skin
and cells of normal estrogen target organs [2], whereas the
HSP70 family includes constitutive (Hsc70 or Hsp73) and
inducible (Hsp70 or Hsp72) members, localized within
both the cytoplasm and the nucleus of all tissue cells [1,3].
Hsp90 is one of the most abundant proteins in mamma-
lian cells [4] and is made up of two isoforms, Hsp90α
(inducible/major form) and Hsp90β (constitutive/minor
form) [5]. Tumour cells appear to be dependent on
increased levels of these proteins, since elevated expres-
sion of different HSPs has been observed in several
human neoplastic conditions [6]. Members of Hsp27,
Hsp70 and Hsp90 families are thought to play a role in
breast cancer [7]: the possible relationship between their
abnormal expression and the prognosis of the disease [8-
17] or the responsiveness to a specific therapy [10,18] has
been studied extensively. It has also been suggested that
HSPs are directly implicated in the drug resistance of
breast cancer cells [19,20]. Nevertheless, HSPs appear to
be promising therapeutic targets for several kinds of
tumours, including breast cancer [21-26].
In veterinary medicine, mammary tumours constitute the
most common malignant neoplasms in the bitch [27];
furthermore, they show wide pathological and clinical
heterogeneity similarly to the disease in humans. Investi-
gations aimed at discovering clinical and pathologic
parameters with prognostic and/or therapeutic signifi-
cance in these neoplasms are considered an important
field of study in this species [28], also in light of the
potential usefulness of the animal model for the study of
human breast cancer.
The aims of this study were to evaluate the immunohisto-
chemical expression of different HSPs in canine malig-
nant mammary tumours and to establish whether this
expression could be correlated to the histological stage of
the neoplasm and overall survival, thus studying the role
of these proteins in the carcinogenesis of the mammary
gland and establishing their potential prognostic and/or
therapeutic implications for this frequent neoplastic con-
dition of the dog.
Methods
Histological examination
The study was carried out on necropsy samples from 3
normal canine mammary glands and surgical samples
from 30 malignant mammary tumours. Ethical approval
for the study was granted by the institutional review board
of the Faculty of Veterinary Medicine, University of Ter-
amo (Italy). All tumour cases were supplied by the
Department of Veterinary Public Health and Animal
Pathology, Faculty of Veterinary Medicine, University of
Bologna (Italy). Samples were fixed in 10% neutral buff-
ered formalin and embedded in paraffin wax. Histological
diagnosis was established using haematoxylin and eosin-
stained slides, according to WHO guidelines [29], while
histological stage of infiltrating tumours was determined
according to the system proposed by Gilbertson et al. [30].
Following these criteria 10 cases revealed in situ carcino-
mas [29], while 20 cases were infiltrating carcinomas fur-
ther grouped as stage I – invasive carcinoma limited to
local structures without identifiable invasion of blood or
lymphatic vessels (10 cases) and stage II – invasion of
blood or lymphatic vessels and/or metastases to regional
lymph nodes (10 cases).
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples were proc-
essed using an immunohistochemical technique with spe-
cific anti-Hsp27 (1:600, rabbit polyclonal, StressGen,
Victoria, BC Canada), anti-Hsp72 (1:100, C92F3A-5,
mouse monoclonal, StressGen), anti-Hsp73 (1:500, 1B5,
rat monoclonal, StressGen) and anti-Hsp90 (1:2500,
AC88, mouse monoclonal, StressGen) antibodies (Abs).
Deparaffined and rehydrated sections were incubated in
3% hydrogen peroxide in absolute methanol for 45 min
in order to inhibit endogenous peroxidase activity, then
rinsed in 0.05 M Tris-buffered saline (TBS), pH 7.6, for 5
min. Antigen retrieval was performed by heat-treating sec-
tions in citrate buffer at pH 6 in a microwave oven for 5
min (3 cycles). To reduce non-specific binding, slides
were incubated in normal goat serum (Biospa, Milan,
Italy) for 10 min at room temperature, before overnight
incubation with primary Ab in a humified chamber at
4°C. After rinsing with TBS, immune complexes were
treated with secondary biotinylated Goat anti-
Mouse&Rabbit (ready-to-use, Biospa, Milan, Italy), or
Rabbit anti-Rat (1:100, DAKO, Copenhagen, Denmark)
Abs and subsequently detected using streptavidin-peroxi-
dase (Biospa, Milan, Italy), both incubated at room tem-
perature for 10 min. Peroxidase activity was detected
using 0.1% hydrogen peroxide in 3-3'-diaminobenzidine
(DAB) solution (Sigma) applied to the tissue sections for
5 min, which were then counterstained with Papanico-
lau's haematoxylin for 5 sec before rinsing, dehydrating
and mounting with coverslips.BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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A negative control was performed in all cases by omitting
the primary Ab and incubating tissue sections with TBS
and/or with an irrelevant antibody directed against an
unrelated antigen such as rabbit anti-human von Wille-
brand factor polyclonal Ab (DAKO, Glostrup, Denmark)
or mouse anti-human desmin monoclonal Ab (DAKO,
Glostrup, Denmark).
Clinical follow-up
Survival data concerning the dogs were supplied by the
Department of Veterinary Public Health and Animal
Pathology, Faculty of Veterinary Medicine, University of
Bologna (Italy). Dogs were clinically examined by veteri-
narians every 3 months after surgical treatment for a min-
imum of 2 years. Follow-up included a radiological
evaluation of the thorax and an ultrasound scan of liver
and kidneys. For the animals that died within the two year
period, overall survival (OS) was considered the months
between surgery and death, whilst for the dogs who sur-
vived >2 years, the OS was the number of months from
surgery to the last clinical examination. OS data in rela-
tion to histological diagnosis and stage are shown in Table
1.
Statistical analysis
A semi-quantitative immunohistochemical assessment
(absent: no positive cells; low: rare positive cells; interme-
diate: up to 50% of positive cells; high: over 50% of posi-
tive cells) was made comparing normal and malignant
mammary gland tissue and, in the latter, comparing
groups (in situ carcinomas, stage I and II infiltrating carci-
nomas) by Chi square test. Influence on survival was
established using the Log-Rank Test and cases were
grouped according to expression: low (absent + low sem-
iquantitative evaluation) or high (intermediate + high
semiquantitative evaluation). Analyses were performed
Table 1: Histological diagnosis, tumour stage and overall survival of the cases comprised in the present study
Histological diagnosis Overall Survival (months)
n° 1 in situ carcinoma 23
n° 2 in situ carcinoma 22
n° 3 in situ carcinoma 36
n° 4 in situ carcinoma 29
n° 5 in situ carcinoma 24
n° 6 in situ carcinoma 27
n° 7 in situ carcinoma 23
n° 8 in situ carcinoma 29
n° 9 in situ carcinoma 60
n° 10 in situ carcinoma 28
STAGE I
n° 1 simple solid carcinoma 24
n° 2 simple tubular carcinoma 27
n° 3 carcinoma in benign tumour 22
n° 4 simple tubulopapillary carcinoma 27
n° 5 carcinoma in benign tumour 22
n° 6 simple solid carcinoma 26
n° 7 simple tubulopapillary carcinoma 33
n° 8 complex carcinoma 24
n° 9 simple tubulopapillary carcinoma 28
n° 10 simple carcinoma 42
STAGE II
n° 1 simple tubulopapillary carcinoma 36
n° 2 simple solid carcinoma 4
n° 3 simple solid carcinoma 1
n° 4 simple solid carcinoma 26
n° 5 simple solid carcinoma 9
n° 6 simple solid carcinoma 24
n° 7 simple solid carcinoma 1
n° 8 carcinoma in benign tumour 12
n° 9 simple tubulopapillary carcinoma 2
n° 10 simple solid carcinoma 26BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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using CSS software (Statsoft, Tulsa, OK) statistics, and a
conventional 5% level was used to define statistical signif-
icance.
Results
HSP expression in normal mammary gland
Hsp27 immunoreactivity was practically absent in normal
canine mammary gland (Figure 1a). When a weak immu-
nohistochemical positivity was detected, it was predomi-
nantly located in the cytoplasm of the alveolar cells, while
both intralobular ductules and extralobular ducts, as well
as myoepithelial cells turned out to be negative. A moder-
ate reactivity of endothelial cells was found in blood ves-
sels.
Hsp72 was focally immunodetected in the cytoplasm and
nucleus of single epithelial cells or isolated alveolar struc-
tures (Figure 1b), while most of the glandular paren-
chyma was negative.
Hsp73 exhibited a strong and diffuse cytoplasmic immu-
nolabelling in alveolar and ductular cells (Figure 1c) and
a less intense and irregular positivity in extralobular duc-
tal structures, while the myoepithelial cells were negative.
Hsp90 showed a moderately intense and diffuse cytoplas-
mic immunostaining in lobular cells (Figure 1d), whereas
extralobular ducts and myoepithelial cells were incon-
stantly positive. In addition, endothelial cells and smooth
muscle tunic of blood vessels often exhibited a moder-
ately intense signal.
HSP expression in malignant mammary tumours
Hsp27 appeared to be absent or weakly expressed in most
tumour cases with no differences among groups; however,
in marginal areas of invasive stages, markedly positive sin-
gle cells or clusters of cells invading the surrounding
stroma were frequently observed (Figure 2). A strong
Hsp27 immunolabelling of cells with squamous metapla-
sia was also found. In in situ carcinomas, myoepithelial
cells showed an intense cytoplasmic signal (Figure 3),
which gradually decreased in the infiltrative stages.
Hsp72 immunolabelling differed among the various
tumours and groups examined, ranging from weak to
strong. The highest signal was observed in tumour areas
displaying infiltrative growth or surrounding inflamma-
tion or necrosis, in which both cytoplasmic and nuclear
localization was detected (Figure 4).
Hsp73 was characterized by a gradually reduced intensity
of immunostaining in in situ and stage I carcinomas, when
compared to that of normal mammary tissue. However, in
stage II, a highly intense immunoreactivity, mainly
located in areas showing infiltrative growth or inflamma-
tion, was detected. Cellular elements undergoing mitosis,
as well as neoplastic lymphatic emboli also exhibited a
strong cytoplasmic positivity (Figure 5).
HSP immunohistochemical expression in normal canine mammary gland tissue Figure 1
HSP immunohistochemical expression in normal canine mammary gland tissue. (a) Hsp27 expression absent; (b) 
focal Hsp72 expression in both the cytoplasm and nucleus of single epithelial cells and isolated alveolar structures; (c) strong 
and diffuse Hsp73 immunolabelling; (d) moderately intense and diffuse Hsp90 immunostaining in lobular cells. Scale bar 20 μm.BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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Hsp90 exhibited a strong and diffuse positivity in all
tumours examined; normal and proliferating myoepithe-
lial cells, observed in complex carcinoma, also showed an
intense immunolabelling (Figure 6). A moderate signal in
cells undergoing mitosis and an intense reactivity in lym-
phatic emboli (Figure 7) were also observed.
Simple solid carcinoma Figure 5
Simple solid carcinoma. Intense Hsp73 immunolabelling in 
lymphatic neoplastic emboli. Scale bar 30 μm.
In situ carcinoma Figure 3
In situ carcinoma. Hsp27 immunoreactivity in myoepithelial 
cells. Scale bar 15 μm.
Simple solid carcinoma Figure 2
Simple solid carcinoma. Clear Hsp27 positivity in infiltrating 
tumour cells. Scale bar 30 μm.
Simple solid carcinoma Figure 4
Simple solid carcinoma. Cytoplasmic and nuclear Hsp72 
expression of neoplastic cells in an inflammatory area. Scale 
bar 30 μm.BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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The immunoreactivity of the HSPs under study did not
show any correlation with a particular histological type of
neoplasm in any of the tumour groups examined.
Comparison of HSP expression in normal mammary gland 
and malignant mammary tumours
In malignant tumours, a significant increase of Hsp27 (P
< 0.01), Hsp72 (P < 0.05) and Hsp90 (P < 0.01) expres-
sion, as well as a significant fall in Hsp73 (P < 0.01)
immunoreactivity was noted compared to normal mam-
mary gland (Figure 8). However when groups were com-
pared, Hsp27 and Hsp72 expression in in situ carcinomas
appeared to be similar to normal mammary gland, while
intermediate and high immunostaining was significantly
associated with invasive stages (P < 0.01). Changes in
Hsp73 expression did not appear to be correlated to inva-
sion, whereas Hsp90 showed a predominantly high
expression in all groups (Figure 9).
Comparison between HSP expression and OS
Survival analysis revealed that Hsp27 was significantly
associated to poor prognosis (P = 0.00087), as its high
immunodetection appeared to be related to a shorter
post-surgical OS. Hsp72 (P = 0.05291) and Hsp73 (P =
0.1693) did not show a significant correlation with OS
(Figure 10). The Log-Rank test could not be used for
Hsp90 because of its high expression in all cases.
Discussion
This study shows that, immunohistochemically, several
HSPs appear to be expressed in normal canine mammary
gland as well as in malignant mammary tumours. In nor-
mal tissue, Hsp90 exhibited a moderately intense immu-
noreactivity, which increased significantly in all the
neoplasms examined, independently of invasion or
tumour histological type. In human breast cancer, abun-
dant Hsp90α expression has also been observed, which
appeared to be closely associated with cell proliferation
[31]. In this respect, Hsp90 is known to be involved in the
regulation of the cell cycle [32], controlling the activity of
several signalling proteins, such as Raf-1 [33], Wee-1 [34]
and Akt [35] kinases. In breast cancer cells, Hsp90 is also
essential for the stability and function of steroid hormone
receptors [36], as well as the membrane receptor tyrosine
kinase ErbB2 [37], whose enhanced expression correlates
with malignancy of breast cancer progression [25] and
which might also play an important role in carcinogenesis
of canine mammary gland [38-41]. Hsp90α expression
has also been reported to indicate a poor prognosis in
human breast cancer [12], pancreatic carcinoma [42], and
acute leukaemia [43]. However, we were unable to find
any prognostic significance for this Hsp probably as a
result of its high immunoreactivity in nearly all of the
cases and in all of the groups examined. Notwithstanding
this, these results suggest that, given its high expression
levels in neoplastic tissues, Hsp90 could hold a funda-
mental role in the multiple processes leading to carcino-
Simple solid carcinoma Figure 7
Simple solid carcinoma. Strong Hsp90 positivity in lymphatic 
neoplastic emboli (arrows). Scale bar 30 μm.
Complex carcinoma Figure 6
Complex carcinoma. Intense and diffuse Hsp90 immunostain-
ing in both neoplastic elements and proliferating myoepithe-
lial cells. Scale bar 30 μm.BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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genesis and tumour progression in the canine mammary
gland. Several in vitro [44-47] and in vivo studies [45-48],
based upon the use of Hsp90-binding agents, such as
geldanamycin derivatives, have indicated this protein as
an alternative molecular target for human breast cancer
therapy. In canine mammary tumours, the immunohisto-
chemical detection of estrogen receptor α has been indi-
cated as a possible parameter for selecting appropriate
future treatment protocols [28]. To our knowledge, the
immunohistochemical expression of HSPs in these neo-
plasms has not been reported in veterinary literature.
However, a recent study has demonstrated a similar pat-
tern of changes in HSPs and apoptosis-associated proteins
in both human and canine mammary tumours, which
lends weight to the use of the canine model to clarify the
molecular mechanisms of mammary carcinogenesis [49].
In particular, Hsp70 and Hsp90 expression, investigated
using Western Blotting, appeared to be significantly
higher in both human and canine neoplasms [49], con-
firming our immunohistochemical results. The intense
Hsp90 immunoreactivity detected in our cases suggests
that this protein could represent a novel molecular target
for adjuvant cancer treatment of canine mammary
tumours, and this animal model could be studied for fur-
ther testing new breast cancer therapy. In addition, since
adjuvant treatments are mainly aimed at controlling
micrometastases, the strong Hsp90, as well as Hsp73,
immunolabelling detected in neoplastic emboli appears
to be remarkable, as it indicates that these HSPs are neces-
sary to cells with metastatic potential and that the inhibi-
tion of their functions could affect the survival of such
cells, which do not always show the same pattern of
expression respect to the primary tumour [50]. The need
for valid in vivo models for further testing Hsp90-targeted
cancer therapy, currently under clinical trial with promis-
ing early results [22,51-53], also appears to be essential, as
a recent study has highlighted a potential contraindica-
tion to this therapy, since the Hsp90 inhibitor, 17-
allylamino-17-demothoxygeldanamicin (17-AAG),
appears to enhance bone metastasis of a human breast
cancer cell line following intracardiac inoculation in the
nude mouse [54].
Comparison of HSP expression in normal mammary glands (NMG) and malignant tumours (MT) Figure 8
Comparison of HSP expression in normal mammary glands (NMG) and malignant tumours (MT). The figure 
shows the percentage of expression of each Hsp (absent, low, intermediate and high) in NMG and MT. In MT, a significant 
increase of Hsp27 (P < 0.01), Hsp72 (P < 0.05) and Hsp90 (P < 0.01) expression, as well as a significant reduction of Hsp73 (P 
< 0.01) immunoreactivity was found with respect to NMG (Chi square test).BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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I n
Comparison of HSP expression among tumour groups Figure 9
Comparison of HSP expression among tumour groups. The figure shows the percentage of expression of each Hsp 
(absent, low, intermediate and high) in in situ and infiltrating malignant tumours, the latter grouped as cases with local stromal 
invasion (St1) or with intravascular invasion (St2). As far as Hsp27 and Hsp72 expression is concerned, the intermediate and 
high immunostaining was found to be significantly associated with invasive stages (P < 0.01) (Chi square test). Hsp73 expression 
did not appear to be correlated to invasion, whereas Hsp90 showed a predominantly high expression in all groups.
Survival curves and results of survival analysis Figure 10
Survival curves and results of survival analysis. Influence on survival was established using the Log-Rank Test and cases 
were grouped according to expression: low (absent + low semiquantitative evaluation) or high (intermediate + high semiquan-
titative evaluation). Hsp27 appeared to be significantly associated to a shorter post-surgical OS (P = 0.00087), while Hsp72 (P 
= 0.05291) and Hsp73 (P = 0.1693) did not show a significant correlation to OS.BMC Cancer 2006, 6:171 http://www.biomedcentral.com/1471-2407/6/171
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 our study, both Hsp90 and Hsp73 exhibited a clear-cut
expression in mitotic cells: Hsp90 seems to regulate the
metaphase-anaphase transition [55], by controlling the
stability of the centrosomal Polo kinase [56], whilst
Hsp73 appears to be localized on the fibres of spindles
and asters during metaphase [57].
Hsp73 also appeared to be constitutively expressed with
strong immunolabelling in normal canine mammary
glands. This finding could be related to its association
with glandular intermediate filaments, such as keratin
polypeptides 8 and 18 [58] and the gradually reducing
Hsp73 immunoreactivity, detected in in situ and stage I
carcinomas, could be related to a partial loss of differenti-
ation in neoplastic cells, which could determine a reduced
expression of typical normal glandular tissue proteins.
On the other hand, the high positivity of HSP70 family
members, frequently detected in areas of intense prolifer-
ative activity and/or stromal invasion, could be correlated
to the roles exerted by these chaperones in cell cycle con-
trol [32] or environmental stress such as hypoxia [59], suf-
fered by these cells, particularly in the more aggressive
tumour areas. Furthermore, in some cases, the presence of
an inflammatory reaction surrounding groups of strongly
positive cells could explain their intense immunoreactiv-
ity, given that the mediators of inflammation are able to
induce HSPs synthesis and increased HSP expression pro-
tects cells from the cytotoxic effects of these substances
[60,61].
Hsp27 appeared to be absent or weakly expressed in nor-
mal canine mammary gland, similarly to humans [2,62].
However, we only observed weak and inconstant expres-
sion of this Hsp in most tumour cases contrary to human
breast cancer in which high levels of Hsp27 have fre-
quently been found [8,10,13,63,64]. Nevertheless, in
stage I and II, infiltrating neoplastic cells, particularly
those peripheral ones often showed an intense immuno-
reactivity for this Hsp. In fact a strict correlation between
Hsp27 over-expression and invasiveness of human breast
cancer cells has been observed in in vitro and in vivo stud-
ies demonstrating that this protein may influence the
invasive and metastatic potential of these cells [65], prob-
ably by controlling their migration on laminin-5 [66].
Furthermore, a synthetic inhibitor of protein kinase C-
dependent phosphorylation of Hsp27 has recently been
demonstrated to block tumour cell migration and inva-
sion [67]. Hsp27 is known to interact with several
cytoskeletal proteins, thus playing an important role in
assembly, remodelling, as well as protection under stress
of the actin cytoskeleton [68-70]. In our cases, these func-
tions could explain Hsp27 immunoreactivity not only in
infiltrative tumour elements, but also in myoepithelial
cells, which also showed Hsp90 positivity. Similar results
have been obtained in the study of human adult salivary
glands, in which the involvement of these HSPs in the
control of the organization of the cytoskeleton was
hypothesized [71]. However, in this study an explanation
for the lack of Hsp27 immunodetection in mioepithelial
cells of normal tissue, as well as for the fall in expression
intensity from in situ to stage II carcinomas, was not given.
In addition, the opposite Hsp27 immunoreactivity
detected in myoepithelial cells of normal mammary gland
and in those ones of in situ tumours is unexpected, since
in situ malignant proliferations are typically characterized
by an intact myoepithelial cell layer, as in normal tissue
[72].
We also observed a strong Hsp27 immunoreactivity in
keratinising cells of tumour areas showing squamous
metaplasia, thus confirming our recent study, which indi-
cated that Hsp27 should be regarded as a differentiation
marker for keratinocytes, both in normal and in neoplas-
tic canine skin [73]. In fact this Hsp exerts prominent roles
in the process of keratinization [74,75].
Finally, only Hsp27 seems to have a prognostic signifi-
cance for survival in these canine neoplasms; its high
immunodetection in invasive tumour stages appears to be
indicative of a poorer clinical outcome, represented in our
cases by a shorter post-surgical OS. In human medicine,
several studies have looked at the prognostic significance
of Hsp27 in breast cancer [10,11,13,15,17], however pro-
ducing conflicting results.
Conclusion
Given their increased immunoreactivity in neoplastic tis-
sues, we believe that Hsp27, Hsp72 and Hsp90 may play
a role in carcinogenesis of the canine mammary gland.
The immunodetection of Hsp90 in tumour cells during
metastatic spread confirms the importance of this protein
as a molecular target for adjuvant cancer therapy and
highlights the possible usefulness of the canine model for
studying human breast cancer. The absent to weak Hsp27
expression both in normal mammary tissue and in in situ
carcinomas, on the other hand, indicates that this protein
is not directly implicated in the physiology or neoplastic
transformation of the canine mammary gland. However
the high Hsp27 immunohistochemical expression
showed by infiltrating tumour cells suggests that this Hsp
is involved in tumour invasiveness and is indicative of a
poor prognosis. To the best of our knowledge the present
study, although preliminary, is the first report of HSP
immunohistochemical expression in normal and neo-
plastic canine mammary glands.
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